EGF is a 6 kDa polypeptide growth factor that has been of particular interest because of its ability to promote wound and ulcer healing when applied topically. [1] A serum containing recombinant EGF produced in barley was examined in an open-label trial in 29 participants of age 30 years with photoaging. [2] The participants completed a survey rating improvements in brown spots, red spots, age spots, and skin smoothness on a 5-point scale, and differences were compared by paired t-tests. The study found that twice daily application of EGF serum for 3 months significantly improved brown spotting, skin texture, pore size, red spotting, and wrinkles versus baseline. Figure 1. Show the effect of barely, human liked EFG serum in the clinical study on 29 women, aged 39-75 with mild to severe wrinkle, fine and course rhytids, photodamage, and pigmentation. The results indicated significant improvement in the appearance of fine lines and rhytids, skin texture, pore size, and various dyschromatic conditions apparent within the first month of use [1].

Fig.1. viable anti-wrinkle effect after 30 day of use topical barely EGF serum

It is well known that EGF is a potent stimulator of cell proliferation of various cells including keratinocytes, fibroblasts and vascular endothelial cells . In addition, EGF stimulates fibroblasts to synthesize increased amount of VEGF and HGF. VEGF and HGF are known to be the most potent cytokines for the promotion of wound angiogenesis. Recent research has demonstrated that simultaneous administration of HGF and VEGF synergistically promotes new blood vessel formation, as compared to administration of each factor alone (fig.2) [2].

Fig.2. Results on quantitative analysis of VEGF production by fibroblast in CDS covered with or without EGF-skin care product; (+) EGF or (−) EGF. *p < 0.01 vs. (−) EGF [Student’s t test].

Different clinical studies in various clinical conditions like scar [3], senile purpura and dermatoporosis [4], hyperpigmentation[5], photo damage [6, 7], under-eye wrinkle and bag [8], radiation dermatitis in cancerous patient [9], leprosy [10] and even non-healing wound [11, 12] showed the beneficial use of topical EGF.

Fig.2. Improvement in under-eye bags and wrinkle after 12 weeks of twice daily infraorbital EGF serum application

Thirty women with various ethnic backgrounds (Chinese, Caucasian and Latino) with an average age of 38 years old participated and mild-moderate visual facial aging signs Two sessions with 2-week intervals were completed using a derma stamp (transdermal drug delivery method) and 2 mL of growth factor serum (AQ Skin Solution recovery serum-contain a mixture of contains a mix of transforming growth factor beta (TGF-β), granulocyte monocyte-colony-stimulating factor, and platelets-derived growth factor with patented technology for extraction and composition at each session. The procedures were carried out for anti-aging and skin rejuvenation. Physician’s global assessment revealed growth factor-induced therapy resulted in skin rejuvenation in all races with 95% confidence, and this increased to 98% confidence for Latinos and Caucasians within the six weeks. Participants’ subjective rating revealed improvement of overall skin appearance with 95% confidence. Most noted improvements were in brightness, skin texture, and tightness [13].

  1. Hardwicke J, Schmaljohann D, Boyce D, Thomas D. Epidermal growth factor therapy and wound healing – past, present and future perspectives. Surgeon. 2008;6(3):172–177.
  2. Schouest JM, Luu TK, Moy RL. Improved texture and appearance of human facial skin after daily topical application of barley produced, synthetic, human-like epidermal growth factor (EGF) serum. J Drugs Dermatol. 2012;11(5):613–620.
  1. Schouest, J.M., T.K. Luu, and R.L. Moy, Improved texture and appearance of human facial skin after daily topical application of barley produced, synthetic, human-like epidermal growth factor (EGF) serum. J Drugs Dermatol, 2012. 11(5): p. 613-20.
  2. Akiko Yamamoto, H.O., Yoshimitsu Kuroyanagi, Evaluation of Epidermal Growth Factor-Incorporating Skin Care Product in Culture Experiment Using Human Fibroblasts. Open Journal of Regenerative Medicine, 2016. 5 (2).
  3. Zoumalan, C.I., et al., Safety and Efficacy of a Scar Cream Consisting of Highly Selective Growth Factors Within a Silicone Cream Matrix: A Double-Blinded, Randomized, Multicenter Study. Aesthet Surg J, 2019. 39(3): p. 319-330.
  4. McKnight, B., R. Seidel, and R. Moy, Topical Human Epidermal Growth Factor in the Treatment of Senile Purpura and the Prevention of Dermatoporosis. J Drugs Dermatol, 2015. 14(10): p. 1147-50.
  5. Kalasho, B.D., et al., Evaluating the Safety and Efficacy of a Topical Formulation Containing Epidermal Growth Factor, Tranexamic Acid, Vitamin C, Arbutin, Niacinamide and Other Ingredients as Hydroquinone 4% Alternatives to Improve Hyperpigmentation: A Prospective, Randomized, Controlled Split Face Study. J Cosmet Sci, 2020. 71(5): p. 263-290.
  6. Mehta, R.C., et al., Reduction in facial photodamage by a topical growth factor product. J Drugs Dermatol, 2008. 7(9): p. 864-71.
  7. Watson, R.E., et al., Repair of photoaged dermal matrix by topical application of a cosmetic ‘antiageing’ product. Br J Dermatol, 2008. 158(3): p. 472-7.
  8. Seidel, R. and R.L. Moy, Reduced appearance of under-eye bags with twice-daily application of epidermal growth factor (EGF) serum: a pilot study. J Drugs Dermatol, 2015. 14(4): p. 405-10.
  9. Kong, M. and S.E. Hong, Topical use of recombinant human epidermal growth factor (EGF)-based cream to prevent radiation dermatitis in breast cancer patients: a single-blind randomized preliminary study. Asian Pac J Cancer Prev, 2013. 14(8): p. 4859-64.
  10. Prakoeswa, C.R.S., et al., The efficacy of topical human amniotic membrane-mesenchymal stem cell-conditioned medium (hAMMSC-CM) and a mixture of topical hAMMSC-CM + vitamin C and hAMMSC-CM + vitamin E on chronic plantar ulcers in leprosy:a randomized control trial. J Dermatolog Treat, 2018. 29(8): p. 835-840.
  11. Tuyet, H.L., et al., The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results. Int Wound J, 2009. 6(2): p. 159-66.
  12. Hanft, J.R., et al., Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. J Wound Care, 2008. 17(1): p. 30-2, 34-7.
  13. Samizadeh, S., Belhaouari, L. Effectiveness of growth factor-induced therapy for skin rejuvenation: A case series. J Cosmet Dermatol. 2021; 20: 1867– 1874.